Benzinga | Apr 30, 2021 12:16PM EDT

Lake Street Initiates Coverage On Castle Biosciences with Buy Rating, Announces Price Target of $94

Lake Street analyst Thomas Flaten initiates coverage on Castle Biosciences (NASDAQ:CSTL) with a Buy rating and announces Price Target of $94.